• Agreement with Rigel Pharmaceuticals to market fostamatinib in Europe and Turkey
  • FDA approval of pretransfusion compatibility analyzer Erytra® Eflexis
  • 5th Edition of the Ethics and Science Awards of Víctor Grífols i Lucas Foundation
  • FDA approval of Babesia detection assay in blood (Procleix® Babesia)
  • PharmacyKeeper application receives KLAS Category Leader award for innovation
  • 1st International Bioethics Congress under the auspices of Víctor Grífols i Lucas Foundation Chair 
  • Announcement of strategic alliance with Shanghai RAAS to reinforce the growth of plasma-derived products and diagnostic solutions in China
  • Presentation of additional results of the AMBAR clinical trial against on Alzheimer’s at AD/PD.
  • Expansion of blood-typing solutions in Latin America and installation of the first Erytra® Eflexis system in Mexico
  • Grifols’ R+D+i efforts receive the top score of “Excellent” by Plan Profarma, an initiative of the Spanish Ministry of Industry, Commerce and Tourism
  • New donation to the World Federation of Hemophilia Humanitarian Aid Program
  • Grifols’ U.S. plasma centers collect more than 113 tons of food to serve people in need in their communities
  • Announcement of EUR 1,400 million capital investment plan between 2018-2022 in General Shareholders’ Meeting
  • The AMBAR project is included among the “Best 100 Ideas of the Year” by Actualidad Económica magazine
  • Reopening of the Grifols Museum in Barcelona
  • Voluntary release of transfers of value made in 2018 to healthcare professionals and organizations in Europe
  • Annual Investor and Analyst Meeting
  • Relocation of subsidiary headquarters in France and Czech Republic to two new office buildings
  • FDA approval of Xembify®, the new 20% subcutaneous immunoglobulin
  • Presentation of additional results of the AMBAR clinical trial against on Alzheimer’s at AAIC
  • Grifols listed on the FTSE4Good Index for the second consecutive year
  • First project in Africa: agreement to build a production line in Morocco for Soludia Maghreb
  • Grifols Asia Pacific receives ISO 9001:2015 certification, an important milestone that recognizes the continuous efforts to improve quality management systems
  • FDA approval for QNext® coagulometer and DG-PT reagent for hemostasis
  • Agreement with diagnostic South Korean firm PCL for the supply of recombinant antigens 
  • Healthcare-technology collaboration agreement signed with Mondragon
  • Grifols Academy of Plasmapheresis Center Leadership Development Program (CLDP) accredited by the Institute for Credentialing Excellence (ICE) for its high standards of quality
  • Production of blood bags begins in the new plant in Brazil
  • Procleix® Panther® System with Automated Ready Technology receives CE marking
  • Two new Progenika Promonitor® kits receive the CE marking and approval in Canada and Australia
  • Agreement with Sandoz to provide Promonitor® kits to Spanish physicians to monitor the pharmaceutical firm’s biologic medicines
  • U.S. launch of AlphaIDTM, a bucal swab used to detect alpha-1 antitrypsin deficiency
  • U.S. and Chinese regulatory authorities approve the strategic alliance between Grifols and Shanghai RAAS
  • Debt refinancing process closed in record time and with strong acceptance 
  • U.S. launch of VistasealTM, Grifols’ first plasma-protein-based biosurgery solution.
  • Presentation of additional results of the AMBAR clinical trial against on Alzheimer’s at CTAD.
  • U.S. launch of Xembify®, the first 20% subcutaneous immunoglobulin to treat primary immunodeficiencies